NeutraKine® IFN beta Monoklonaler Antikörper

NeutraKine® IFN beta Monoklonal Antikörper für Neutralization, ELISA

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human und mehr (1)

Anwendung

Neutralization, ELISA

Konjugation

Unkonjugiert

Publikationen

2

CloneNo.

2C6E5

Kat-Nr. : 69013-1-Ig

Synonyme

Fibroblast interferon, IFB, IFF, IFN beta, IFNB, IFNB1, IFN-beta, Interferon beta, interferon, beta 1, fibroblast, NeutraKine® IFN beta

---

Galerie der Validierungsdaten

• 

  Neutralization experiment of NeutraKine® IFN beta using 69013-1-Ig

  Recombinant IFN beta (Cat.NO. HZ-1298) inhibits TF-1 cell proliferation at dose dependent manner (blue curve, refer to bottom X-left Y). The activity of human IFN beta (10 ng/mL HZ-1298) is neutralized by mouse anti-human IFN beta monoclonal antibody 69013-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 5-20 ng/mL.

---

Neutralization

Produktinformation

69013-1-Ig bindet in Neutralization, ELISA NeutraKine® IFN beta und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human, Maus
• Wirt / Isotyp: Maus / IgG1
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: human Humankine IFN beta protein HZ-1298
• Vollständiger Name: IFN beta
• Gene symbol: IFNB1
• Gene ID (NCBI): 3456
• Konjugation: Unkonjugiert
• Form: Lyophilized Powder
• Reinigungsmethode: Protein-G-Reinigung
• Lagerungspuffer: Sterile PBS.
• Endotoxin: <0.1 EU/μg
• Wiederherstellung: This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
• Stability and Storage: Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Hintergrundinformationen

Interferon beta (IFN beta) is a cytokine that is naturally produced by the immune system in response to biological and chemical stimuli. It signals by binding to the heterodimeric type I IFN receptor composed of the IFNAR1 and IFNAR2 chains, and regulates the expression of a plethora of genes by means of the classical JAK/STAT and other pathways. Interferon beta (IFN beta) has been shown in several clinical trials to have efficacy in multiple sclerosis. Interferon beta gene therapy is expected to become widely available for clinical use in cancer patients, and this new strategy might be extended to molecular targeting therapy, or used in combination with cell therapy or other therapies.

This antibody can be used to neutralize the bioactivity of IFN beta.

Publikationen

Species	Application	Title
human	Neutralization	Nat Commun; Ebola virus VP35 hijacks the PKA-CREB1 pathway for replication and pathogenesis by AKIP1 association.; Authors - Lin Zhu
mouse	Neutralization	Cell Rep; Targeting TCF19 sensitizes MSI endometrial cancer to anti-PD-1 therapy by alleviating CD8+ T cell exhaustion via TRIM14-IFN-β axis; Authors - Xinyue Ma